| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Solid TumorsClinical Diagnosis-Solid Tumors Posters |
1 Research Center for Child Mental Development, Hamamatsu University School of Medicine, Hamamatsu, Japan; 2 Positron Medical Center, Hamamatsu Medical Center, Hamamatsu, Japan; 3 Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan; 4 Molecular Imaging Frontier Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan
1498
Objectives: This study was designed to assess tumor FDG uptake as a predictor of local control (LC) and disease-free survival (DFS) in patients with head and neck cancer.
Methods: FDG-PET was prospectively studied on 50 patients with newly diagnosed head and neck squamous cell cancer, including tumors of pharynx, larynx, gingiva, tongue and maxillary sinus. SUV of the primary tumor was measured for the survival analyses.
Results: For the prediction of clinical outcome, low SUVs (
7.0) predicted significantly higher rates of 2-year LC (p = 0.0067) and DFS (p = 0.0051) as compared to high SUVs (> 7.0). In the Cox proportional hazard model, tumor SUV was a significant and independent predictor of LC (p = 0.022) and DFS (p = 0.019). In addition, tumor SUV as a continuous variable was also significantly predictive of both LC (p = 0.0043) and DFS (p = 0.0032). The LC and DFS hazard ratios for tumor SUV remained significant when adjusted for N-stage and age in the bivariate analyses.
Conclusions: Our study demonstrated the utility of baseline primary tumor SUV as an independent predictor of treatment outcome in patients with head and neck cancer. We also found tumor SUV, presented as a continuous variable, was significantly predictive of clinical outcome. Therefore, patients with higher FDG uptake should be considered for more aggressive treatment approach.
| ||||||||||||||||||||||||||||||||||||||
